Skip to main content

Advertisement

SpringerLink
Log in

Surveillance of resected non-small cell lung cancer

  • Educational Series – Red Series*
  • New Trends in Clinical Oncology
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Lung cancer is the most common cancer in the world. 15 % of all patients with lung cancer are diagnosed at an early stage, and surgery is the treatment of choice for them. 40 % of all patients survive more than 5 years after surgery, and most of them die as a result of systemic disease. Half of all recurrences are diagnosed within the first 24 months after curative treatment, and 90 % in the first 5 years. Despite this, it is not standardized who should do the monitoring, what additional tests are needed and how often should they be performed. We present here a review on the various recommendations in clinical guidelines.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Non-small Cell Lung Cancer Collaborative Group (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311:899–909

    Article  Google Scholar 

  2. Mountain CF (1986) A new international staging system for lung cancer. Chest 89:225–233

    Google Scholar 

  3. Harpole DH (1995) A prognostic model of recurrence and death in stage I non-small cell lung utilizing presentation histopathology and oncoprotein expression. Cancer Res 55:51–56

    PubMed  CAS  Google Scholar 

  4. Pairolero PC (1984) Postsurgical stage I bronchogenic carcinoma: morbid implications of recurrent disease. Ann Thorac Surg 38:331–336

    Article  PubMed  CAS  Google Scholar 

  5. Virgo KS (1996) Cost of patient follow-up after potentially curative lung cancer treatment. J Thorac Cardiovasc Surg 112:356–363

    Article  PubMed  CAS  Google Scholar 

  6. Shields TW (1978) Long-term survivors after resection of lung carcinoma. J Thorac Cardiovasc Surg 76:439–445

    PubMed  CAS  Google Scholar 

  7. Frank A et al (1995) Decision logic for retreatment of asymptomatic lung cancer recurrence based on positron emission tomography findings. Int J Radiat Oncol Biol Phys 32(5):1495–1512

    Article  PubMed  CAS  Google Scholar 

  8. Di Maio M (2010) Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy: a prognostic score from individual data of nine randomised trials. Eur J Cancer 46(4):735–743

    Article  PubMed  Google Scholar 

  9. Jemal A, Thomas A, Murray T (2002) Cancer statistics 2002. CA Cancer J Clin 52:23–45

    Article  PubMed  Google Scholar 

  10. Lamont JP (2002) Systematic postoperative radiologic follow-up in patients with non-small cell lung cancer for detecting second primary lung cancer in stage IA. Arch Surg 137(8):935–938

    Article  PubMed  Google Scholar 

  11. Gilbert S et al (2000) Who should follow up lung cancer patients after operation? Ann Thorac Surg 69:1696–1700

    Article  PubMed  CAS  Google Scholar 

  12. Varela G (1998) Follow-up of patients with non-small-cell pulmonary cancer undergoing complete resection. Should surgeons be in charge? Arc Bronconeumol 34(1):14–6

    Google Scholar 

  13. Moore S et al (2002) Nurse led follow up and conventional medical follow up in management of patients with lung cancer: randomised trial. BMJ 325:1145–1152

    Article  PubMed  Google Scholar 

  14. Naunheim KS (1995) Clinical surveillance testing after lung cancer operations. Ann Thorac Surg 60:1612

    Article  PubMed  CAS  Google Scholar 

  15. Virgo KL (1995) Post-treatment management options for patients with lung cancer. Ann Surg 222:700–710

    Article  PubMed  CAS  Google Scholar 

  16. Walsh GL (1995) Is follow-up of lung cancer patients after resection medically indicated and cost-effective? Ann Thorac Surg 60(6):1563–1570

    Article  PubMed  CAS  Google Scholar 

  17. Younes R (1999) Follow-up in lung cancer: how often and for what purpose? Chest 115(6):1494–1499

    Article  PubMed  CAS  Google Scholar 

  18. Egermann U (2002) Regular follow-up after curative resection of non-small cell lung cancer: a real benefit for patients. Eur Respir J 19(3):464–468

    Article  PubMed  CAS  Google Scholar 

  19. Westeel V et al (2007) Protocole IFCT-0302: essai randomise de deux schémas de surveillance dans les cancers bronchiques non à petites cellules complètement réséqués. Rev Mal Respir 24:645–652

    Article  PubMed  CAS  Google Scholar 

  20. Tufman A et al (2010) Biological markers in lung cancer: a clinician’s perspective. Cancer Biomark 6(3–4):123–135

    PubMed  Google Scholar 

  21. Ghosal R et al (2009) A review of novel biological tools used in screening for the early detection of lung cancer. Postgrad Med J 85(1005):358–363

    Article  PubMed  CAS  Google Scholar 

  22. Cho S, Lee EG (2010) A follow-up of integrated positron emission tomography/computed tomography after curative resection of non-small-cell lung cancer in asymptomatic patients. J Thorac Cardiovasc Surg 139(6):1447–1451

    Article  PubMed  Google Scholar 

  23. Isobe K et al (2009) Usefulness of fluoro-2-deoxyglucose positron emission tomography for investigating unexplained rising carcinoembryonic antigen levels that occur during the postoperative surveillance of lung cancer patients. Int J Clin Oncol 14(6):497–501

    Article  PubMed  CAS  Google Scholar 

  24. Kanzaki R et al (2010) Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients. Interact Cardiovasc Thorac Surg 10(6):1009–1014

    Article  PubMed  Google Scholar 

  25. Rosell R (2009) Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361:958–967

    Article  PubMed  CAS  Google Scholar 

  26. Carlson JJ (2009) Epidermal growth factor receptor genomic variation in NSCLC patients receiving tyrosine kinase inhibitor therapy: a systematic review and meta-analysis. J Cancer Res Clin Oncol 135(11):1483–1493

    Article  PubMed  CAS  Google Scholar 

  27. Dahabreh IJ (2010) Somatic EGFR mutation and gene copy gain as predictive biomarkers for response to tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 16(1):291–303

    Article  PubMed  CAS  Google Scholar 

  28. Massarelli E (2007) KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res 13(10):2890–2896

    Article  PubMed  CAS  Google Scholar 

  29. Linardou H (2008) Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol 9(10):962–972

    Article  PubMed  CAS  Google Scholar 

  30. Takeda M (2010) De novo resistance to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutation-positive patients with non-small cell lung cancer. J Thorac Oncol 5(3):399–400

    Article  PubMed  Google Scholar 

  31. Carpagnano GE et al (2008) New biomolecular methodologies in diagnosis of lung cancer. Recenti Prog Med 99(9):417–421

    PubMed  Google Scholar 

  32. Han W et al (2009) Gene promoter methylation assayed in exhaled breath, with differences in smokers and lung cancer patients. Respir Res 25(10):86

    Article  Google Scholar 

  33. Belinsky SA et al (2002) Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers. Cancer Res 62(8):2370–2377

    PubMed  CAS  Google Scholar 

  34. Horváth I et al (2009) Exhaled biomarkers in lung cancer. Eur Respir J 34(1):261–275

    Article  PubMed  Google Scholar 

  35. Carpagnano GE et al (2010) Cigarette smoke and increased COX-2 and surviving levels in exhaled breath condensate of lung cancer patients: how hot is the link? Lung Cancer 67(1):108–113

    Article  PubMed  Google Scholar 

  36. Hsu HS et al (2007) Multiple genetic and epigenetic biomarkers for lung cancer detection in cytologically negative sputum and a nested case-control study for risk assessment. J Pathol 213(4):412–419

    Article  PubMed  CAS  Google Scholar 

  37. Gomperts BN et al (2010) Lung cancer biomarkers: FISHing in the sputum for risk assessment and early detection. Cancer Prev Res (Phila Pa) 3(4):420–423

    Article  CAS  Google Scholar 

  38. Varella-Garcia M et al (2010) The detection of chromosomal aneusomy by fluorescence in situ hybridation in sputum predicts lung cancer incidence. Cancer Prev Res (Phila Pa) 3(4):447–453

    Article  CAS  Google Scholar 

  39. Wang H et al (2010) Expression of Hsp27 and Hsp70 in lymphocytes and plasma in healthy workers and coal miners with lung cancer. J Huazhong Univ Sci Technolog Med Sci 30(4):415–420

    Article  PubMed  CAS  Google Scholar 

  40. Gube M et al (2011) Performance of biomarkers SMRP, CA125, and CYFRA 21-1 as potential tumor markers for malignant mesothelioma and lung cancer in a cohort of workers formerly exposed to asbestos. Arch Toxicol 85(3):185–192

    Google Scholar 

  41. Hsu HS et al (2007) Characterization of a multiple epigenetic marker panel for lung cancer detection and risk assessment in plasma. Cancer 110(9):2019–2026

    Article  PubMed  CAS  Google Scholar 

  42. Gao K (2009) Systemic disease-induced salivary biomarker profiles in mouse models of melanoma and non-small cell lung cancer. PLoS One 4(6):e5875

    Article  PubMed  Google Scholar 

  43. Rubins J et al (2007) Follow-up and surveillance of the lung cancer patient following curative intent therapy: ACCP evidence-based clinical practice guideline (2nd edition). Chest 132(3 Suppl):355S–367S

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

The authors declare that there is no conflict of interest in relation to this article.

Author information

Authors and Affiliations

  1. Servicio Oncología Médica, Hospital Universitario Puerta de Hierro Majadahonda, Calle Manuel de Falla, s/n, Majadahonda, 28020, Madrid, Spain

    A. López-González, P. Ibeas Millán, B. Cantos & M. Provencio

Authors
  1. A. López-González
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. Ibeas Millán
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. B. Cantos
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Provencio
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Provencio.

Additional information

*Supported by an unrestricted educational grant from MSD Oncology.

Rights and permissions

Reprints and permissions

About this article

Cite this article

López-González, A., Ibeas Millán, P., Cantos, B. et al. Surveillance of resected non-small cell lung cancer. Clin Transl Oncol 14, 721–725 (2012). https://doi.org/10.1007/s12094-012-0841-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-012-0841-z

Keywords

Search

Navigation